It is of note that, the targeting of PI3K and its downstream kinases by single-agent inhibitors has limited efficacy with the exception of the PI3K p110δ-selective inhibitors, which target the tumour stroma and have shown a remarkable clinical activity in CLL52. The gene discussed is PIK3CA; the disease is neoplasm.